Show simple item record

dc.contributor.authorMoorcraft, SYen_US
dc.contributor.authorBegum, Ren_US
dc.contributor.authorCunningham, Den_US
dc.contributor.authorPeckitt, Cen_US
dc.contributor.authorBaratelli, Cen_US
dc.contributor.authorGillbanks, Aen_US
dc.contributor.authorRogers, Pen_US
dc.contributor.authorNwokorie, Ven_US
dc.contributor.authorChau, Ien_US
dc.contributor.authorWatkins, Den_US
dc.contributor.authorStarling, Nen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-02-15T12:18:16Z
dc.date.issued2017-09en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/27839727en_US
dc.identifierS1533-0028(16)30202-Xen_US
dc.identifier.citationClin Colorectal Cancer, 2017, 16 (3), pp. e181 - e189en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1098
dc.identifier.eissn1938-0674en_US
dc.identifier.doi10.1016/j.clcc.2016.09.008en_US
dc.description.abstractBACKGROUND: Research biopsies are an increasingly important component of clinical trials, but there are concerns that biopsies may deter patients from participating in research. PATIENTS AND METHODS: Patients participating in a single-center study investigating the feasibility of molecular profiling in advanced gastrointestinal cancers were asked to complete a questionnaire regarding their reasons for consenting/declining optional research biopsies and blood samples. These samples were mainly for exploratory translational research and were unlikely to influence patients' treatment. RESULTS: One hundred ninety-six (88%) of the 222 patients registered in the study completed the questionnaire. One hundred twenty-six patients (64%) stated they consented to a biopsy and 180 patients (92%) to blood sample collection. Male patients (P = .033) and patients with a good performance status (PS) were more willing to consent to a biopsy (79% for PS 0, 63% for PS 1, 43% for PS 2; P = .012). Eighty-eight patients (70%) who consented to a biopsy gave an altruistic reason (eg, to help research and/or others) as a reason why they consented. Only 8 patients (6%) consented solely because they believed it might influence their treatment. Reasons for declining biopsies included a wish to avoid additional procedures (n = 18; 29%) and previous unpleasant biopsy experiences (n = 9; 15%). CONCLUSION: Many patients with advanced gastrointestinal cancer appear willing to undergo biopsies for exploratory research purposes. In our study, patients who consented to a biopsy mainly did so for altruistic reasons and/or a wish to contribute to scientific research.en_US
dc.format.extente181 - e189en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectAltruismen_US
dc.subjectBlood samplingen_US
dc.subjectConsenten_US
dc.subjectMotivationsen_US
dc.subjectTranslational researchen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAltruismen_US
dc.subjectAttitude to Healthen_US
dc.subjectBiomedical Researchen_US
dc.subjectBiopsyen_US
dc.subjectFemaleen_US
dc.subjectGastrointestinal Neoplasmsen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectResearch Subjectsen_US
dc.subjectSurveys and Questionnairesen_US
dc.titleAttitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-22en_US
rioxxterms.versionofrecord10.1016/j.clcc.2016.09.008en_US
rioxxterms.licenseref.startdate2017-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClin Colorectal Canceren_US
pubs.issue3en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume16en_US
pubs.embargo.terms12 monthsen_US
icr.researchteamGastrointestinal Cancers Clinical Trialsen_US
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden_US
dc.contributor.icrauthorChau, Ianen_US
dc.contributor.icrauthorStarling, Naureenen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record